Provided by Tiger Trade Technology Pte. Ltd.

Organogenesis Holdings Inc

1.63
-0.0900-5.23%
Post-market: 1.680.0500+3.07%16:44 EDT
Volume:1.06M
Turnover:1.75M
Market Cap:209.68M
PE:-2.04
High:1.71
Open:1.70
Low:1.62
Close:1.72
52wk High:7.08
52wk Low:1.54
Shares:128.64M
Float Shares:61.06M
Volume Ratio:2.05
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8009
EPS(LYR):0.1500
ROE:-25.92%
ROA:-4.11%
PB:1.41
PE(LYR):10.87

Loading ...

Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks

Simply Wall St.
·
Aug 21

Truist Financial Sticks to Its Hold Rating for Organogenesis Holdings (ORGO)

TIPRANKS
·
Aug 13

Organogenesis Shares Plunge After Revenue Slump, Wider Loss and Lower Outlook

Dow Jones
·
Aug 08

Organogenesis price target lowered to $2 from $3 at Truist

TIPRANKS
·
Aug 07

Truist Adjusts Price Target on Organogenesis to $2 From $3, Maintains Hold Rating

MT Newswires Live
·
Aug 07

Organogenesis Enters $75 Million At-the-Market Equity Sales Agreement

Reuters
·
Aug 07

Organogenesis Holdings Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Organogenesis Hldgs Q2 Sales $100.779M Beat $54.250M Estimate

Benzinga Earnings
·
Aug 07

Organogenesis Q2 Net Product Revenue USD 42.8 Million

Reuters
·
Aug 07

Organogenesis Outlook FY Net Product Revenue USD 179-215 Million

THOMSON REUTERS
·
Aug 07

Organogenesis Q2 EPS USD -0.77

THOMSON REUTERS
·
Aug 07

Organogenesis Holdings Inc. Expected to Post a Loss of 35 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Organogenesis Affinity meets primary endpoint in complex venous leg ulcer trial

TIPRANKS
·
Jul 28

Organogenesis Says RCT Shows Affinity Lifts Venous Leg Ulcer Closure Rates at Weeks 12 and 16

Reuters
·
Jul 28

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

THOMSON REUTERS
·
Jul 28

3 Penny Stocks With Market Caps Over $100M To Consider

Simply Wall St.
·
Jul 20

Organogenesis to Report Q2 Fiscal 2026 Results After Market Close, Host Conference Call

Reuters
·
Jul 09

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

GlobeNewswire
·
Jul 09

FDA Accepts Organogenesis' Biologics License Application for Renu

Reuters
·
Jul 07

Organogenesis announces FDA acceptance of ReNu biologics license application

TIPRANKS
·
Jul 07